Sentry Investment Management LLC raised its position in Waters Co. (NYSE:WAT) by 11.7% during the fourth quarter, HoldingsChannel reports. The firm owned 6,128 shares of the medical instruments supplier’s stock after buying an additional 641 shares during the quarter. Sentry Investment Management LLC’s holdings in Waters were worth $1,184,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of WAT. Bristlecone Advisors LLC purchased a new position in Waters in the third quarter valued at about $175,000. Advisory Services Network LLC lifted its position in shares of Waters by 6.0% in the second quarter. Advisory Services Network LLC now owns 1,145 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 65 shares during the last quarter. Checchi Capital Advisers LLC acquired a new stake in shares of Waters in the fourth quarter worth about $210,000. Carnick & Kubik Group LLC acquired a new stake in shares of Waters in the third quarter worth about $246,000. Finally, Zions Bancorporation lifted its position in shares of Waters by 12,075.0% in the third quarter. Zions Bancorporation now owns 1,461 shares of the medical instruments supplier’s stock worth $262,000 after buying an additional 1,449 shares during the last quarter. Hedge funds and other institutional investors own 91.58% of the company’s stock.

In other news, Director Joann A. Reed sold 1,386 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $194.07, for a total value of $268,981.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Elizabeth B. Rae sold 28,400 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $219.01, for a total value of $6,219,884.00. Following the completion of the sale, the senior vice president now owns 13,443 shares in the company, valued at $2,944,151.43. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,789 shares of company stock valued at $26,083,647. Insiders own 5.07% of the company’s stock.

A number of analysts have weighed in on WAT shares. Zacks Investment Research cut Waters from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. Barclays reaffirmed a “hold” rating and issued a $202.00 price target on shares of Waters in a research report on Monday, January 8th. Deutsche Bank boosted their price target on Waters from $199.00 to $200.00 and gave the stock a “hold” rating in a research report on Wednesday, October 25th. JPMorgan Chase & Co. boosted their price target on Waters from $180.00 to $200.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 24th. Finally, Citigroup reaffirmed a “neutral” rating and issued a $180.00 price target on shares of Waters in a research report on Wednesday, October 25th. Twelve research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $203.75.

Waters Co. (NYSE WAT) opened at $200.20 on Wednesday. Waters Co. has a 12-month low of $148.72 and a 12-month high of $220.20. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.97 and a current ratio of 2.10. The firm has a market capitalization of $15,783.33, a PE ratio of 26.46, a P/E/G ratio of 2.38 and a beta of 0.88.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, January 23rd. The medical instruments supplier reported $2.51 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.07. The business had revenue of $687.28 million during the quarter, compared to analysts’ expectations of $671.98 million. Waters had a return on equity of 24.70% and a net margin of 0.88%. The firm’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.21 EPS. analysts forecast that Waters Co. will post 8.16 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2018/02/14/waters-co-wat-shares-bought-by-sentry-investment-management-llc.html.

Waters Company Profile

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Co. (NYSE:WAT).

Institutional Ownership by Quarter for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.